


**Product Name** : Encorafenib  
**Cat. No.** : PC-49770  
**CAS No.** : 1269440-17-6  
**Molecular Formula** : C<sub>22</sub>H<sub>27</sub>ClFN<sub>7</sub>O<sub>4</sub>S  
**Molecular Weight** : 540.01  
**Target** : Raf  
**Solubility** : 10 mM in DMSO



## Biological Activity

Encorafenib (NVP-LGX818, LGX818) a potent, selective **BRAF** inhibitor with IC<sub>50</sub> of 0.35, 0.47, and 0.3 nM against BRAF V600E, wild-type BRAF and CRAF in vitro cell-free assays, respectively.

Encorafenib (NVP-LGX818, LGX818) is able to bind to other kinases in vitro including JNK1, JNK2, JNK3, LIMK1, LIMK2, MEK4, and STK36 and significantly reduce ligand binding to these kinases at clinically achievable concentrations (<0.9 uM).

Encorafenib (NVP-LGX818, LGX818) inhibited the in vitro cell growth of tumor cell lines that express BRAF V600 E, D, and K mutations.

Encorafenib (NVP-LGX818, LGX818) induced tumor regressions associated with RAF/MEK/ERK pathway suppression in mice implanted with tumor cells expressing the BRAF V600E mutation.

## References

Adelmann CH, et al. *Oncotarget*. 2016 May 24;7(21):30453-60.

Krepler C, et al. *Clin Cancer Res*. 2016 Apr 1;22(7):1592-602.

van Geel RMJM, et al. *Cancer Discov*. 2017 Jun;7(6):610-619.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com